#31
|
|||
|
|||
ïðèñîåäèíÿþñü ê àíãèîãðàôèñòàì, ðîþùèì ñåáå ìîãèëó è âîñõâàëÿþùèì ÌÑÊÒ (64 ñðåçà):
Atlas of Non-Invasive Coronary Angiography by Multidetector Computed Tomography (2006 ã). Êðàñèâûå êàðòèíêè è äîñòàòî÷íî ïîíÿòíî íàïèñàíî. [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] |
#32
|
|||
|
|||
ACC/AHA 2008 Guidelines for the Management of Adults With Congenital Heart Disease
First-ever guidelines offer cardiologists comprehensive tools for managing lifetime care
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] |
#33
|
|||
|
|||
JUPITER
Paul M Ridker et al.
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein. NEJM 2008. Background Increased levels of the inflammatory biomarker high-sensitivity C-reactive protein predict cardiovascular events. Since statins lower levels of high-sensitivity C-reactive protein as well as cholesterol, we hypothesized that people with elevated high-sensitivity C-reactive protein levels but without hyperlipidemia might benefit from statin treatment. Methods We randomly assigned 17,802 apparently healthy men and women with low-density lipoprotein (LDL) cholesterol levels of less than 130 mg per deciliter (3.4 mmol per liter) and high-sensitivity C-reactive protein levels of 2.0 mg per liter or higher to rosuvastatin, 20 mg daily, or placebo and followed them for the occurrence of the combined primary end point of myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or death from cardiovascular causes. Results The trial was stopped after a median follow-up of 1.9 years (maximum, 5.0). Rosuvastatin reduced LDL cholesterol levels by 50% and high-sensitivity C-reactive protein levels by 37%. The rates of the primary end point were 0.77 and 1.36 per 100 person-years of follow-up in the rosuvastatin and placebo groups, respectively (hazard ratio for rosuvastatin, 0.56; 95% confidence interval [CI], 0.46 to 0.69; P<0.00001), with corresponding rates of 0.17 and 0.37 for myocardial infarction (hazard ratio, 0.46; 95% CI, 0.30 to 0.70; P=0.0002), 0.18 and 0.34 for stroke (hazard ratio, 0.52; 95% CI, 0.34 to 0.79; P=0.002), 0.41 and 0.77 for revascularization or unstable angina (hazard ratio, 0.53; 95% CI, 0.40 to 0.70; P<0.00001), 0.45 and 0.85 for the combined end point of myocardial infarction, stroke, or death from cardiovascular causes (hazard ratio, 0.53; 95% CI, 0.40 to 0.69; P<0.00001), and 1.00 and 1.25 for death from any cause (hazard ratio, 0.80; 95% CI, 0.67 to 0.97; P=0.02). Consistent effects were observed in all subgroups evaluated. The rosuvastatin group did not have a significant increase in myopathy or cancer but did have a higher incidence of physician-reported diabetes. Conclusions In this trial of apparently healthy persons without hyperlipidemia but with elevated high-sensitivity C-reactive protein levels, rosuvastatin significantly reduced the incidence of major cardiovascular events. (ClinicalTrials.gov number, NCT00239681 [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] .) Ïðèìåíåíèå ñòàòèíîâ íàèáîëåå ýôôåêòèâíî ïðè âûñîêîì ðèñêå ðàçâèòèÿ ñåðäå÷íî-ñîñóäèñòûõ îñëîæíåíèé. Àâòîðû èññëåäîâàíèÿ Jupiter ïîäíèìàþò âîïðîñ î "ïåðâè÷íîì" ïðèåìå ñòàòèíîâ ó ïàöèåíòîâ ñ âûñîêèì óðîâíåì Ñ-ðåàêòèâíîãî áåëêà.  èññëåäîâàíèå áûëî âêëþ÷åíî áîëåå 17 òûñ. ïàöèåíòîâ, êà÷åñòâî ðàáîòû âûñîêîå. Óâàæàåìûå êîëëåãè, ñ÷èòàåòå ëè Âû, ÷òî äàííûå ýòîãî èññëåäîâàíèÿ ðåàëüíî èçìåíÿò Âàøó êëèíè÷åñêóþ ïðàêòèêó: 1. Áóäåòå ëè Âû òåïåðü ÷àùå áðàòü êðîâü íà ÑÐÁ? 2. Ïðè ÑÐÁ áîëåå 2, áóäåòå ëè Âû ðåêîìåíäîâàòü ïðèåì ñòàòèíîâ? |
#34
|
|||
|
|||
×òîáû ïðåäîòâðàòèòü 2,5 ñìåðòè íà 1000 ÷åëîâåêî-ëåò îò ëþáûõ ïðè÷èí íåîáõîäèìî ëå÷èòü ïî÷òè äâà ãîäà ðîçóâàñòàòèíîì â äîçå 20 ìã.
|
#35
|
|||
|
|||
ACC/AHA 2008 Performance Measures for Adults With ST-Elevation and Non–ST-Elevation Myocardial Infarction
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] ACC/AHA 2008 Statement on Performance Measurement and Reperfusion Therapy [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] |
#36
|
|||
|
|||
ïðî ñòåíòû
Ñðàâíåíèå ðåçóëüòàòîâ DES b BMS ó äèàáåòèêîâ ðåòðîñïåêòèâíûé àíàëèç. DES ëó÷øå.
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] |
#37
|
|||
|
|||
Ëåíü - ýòî íå òîëüêî ðîññèéñêèé ìåíòàëèòåò.
Ñïåöèàëüíàÿ îáðàçîâàòåëüíàÿ ïðîãðàììà äëÿ ðîäñòâåííèêîâ áîëüíûõ ñ CVD ïîêàçàëà íèçêóþ ïðèâåðæåííîñòü ê ðåêîìåíäàöèÿì ó çäîðîâûõ.
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] |
|
#38
|
||||
|
||||
Randomized Clinical Trials and Observational Studies: Guidelines for Assessing Respective Strengths and Limitations
J. Am. Coll. Cardiol. Intv. 2008;1;211-217 Edward L. Hannan [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] |
#39
|
|||
|
|||
Íàòêíóëñÿ íà ñòàòüþ: Ãîëûé ñòåíò íå õóæå ïîêðûòîãî ïðè âìåøàòåëüñòâå íà áîëüøèõ ÊÀ. [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
|
#40
|
|||
|
|||
Ïðî äåïðåññèþ ó ïàöèåíòîâ ñ ÕÑÍ è ïðèìåíåíèå àíòèäåïðåññàíòîâ: Antidepressants ‘do not decrease survival’ in HF patients [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] |
#41
|
||||
|
||||
Èññëåäîâàíèå SHUNT íå ïîêàçàëî âçàèìîñâÿçè ìåæäó íàëè÷èåì ÎÎÎ è ìèãðåíüþ:
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
__________________
Àáóãîâ Ñåðãåé Àëåêñàíäðîâè÷. Ðîññèéñêèé Íàó÷íûé Öåíòð Õèðóðãèè èì. àêàäåìèêà Á.Â. Ïåòðîâñêîãî. |
#42
|
||||
|
||||
Îïòèìàëüíûé âîçðàñò äëÿ íà÷àëà ïåðâè÷íîé ïðîôèëàêòèêè àñïèðèíîì ó ìóæ÷èí - 47 ëåò, ó æåíùèí - 58 ëåò.
Óâû, íåò ïîëíîãî òåêñòà. Age threshold for vascular prophylaxis by aspirin in patients without diabetes Heart 2008;94:1429-1432 È åùå, èíòåðåñíàÿ ñòàòüÿ... PCI after lytic therapy: when and how? [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] |
#43
|
||||
|
||||
Öèòàòà:
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] |
#44
|
||||
|
||||
Ïîïîñëåäíåìó ESC2007 ãàéäó ïî Àà àñïèðèí ó ïàöèåíòîâ ñ Àà (áåç äðóãèõ ïîêàçàíèé ê àñïèðèíó) íàçíà÷àåòñÿ ñ 50 ëåò ((47+58) : 2=52,5), ïî÷òè òî÷íî.
|
#45
|
||||
|
||||
Öèòàòà:
Àñïèðèí óáèâàåò áîëüíûõ ÈÌ, ðîæä¸ííûõ ïîä çíàêàìè Áëèçíåöû è Âåñû. Êîëè÷åñòâî áîëüíûõ - îãðîìíîå, äîñòîâåðíîñòü - îãðîìíàÿ, òåñò ìåæãðóïïîâîãî âçàèìîäåéñòâèÿ - äîñòîâåðåí ñ îãðîìíîé ñèëîé.
__________________
Àáóãîâ Ñåðãåé Àëåêñàíäðîâè÷. Ðîññèéñêèé Íàó÷íûé Öåíòð Õèðóðãèè èì. àêàäåìèêà Á.Â. Ïåòðîâñêîãî. |